What's in Lindenhofgruppe AG's pipeline?

Lindenhofgruppe AG has 3 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Lindenhofgruppe AG's portfolio?

Top competitors by shared drug class: US Department of Veterans Affairs.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lindenhofgruppe-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Lindenhofgruppe AG — Portfolio Competitive Intelligence Brief

Lindenhofgruppe AG pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
BACTROBAN® Nasal ong	BACTROBAN® Nasal ong	marketed	Topical antibiotic	Isoleucyl-tRNA synthetase	Infectious Disease

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

US Department of Veterans Affairs · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lindenhofgruppe AG:

Cite this brief

Drug Landscape (2026). Lindenhofgruppe AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lindenhofgruppe-ag. Accessed 2026-05-16.